Sangamo price target lowered to $5 from $15 at H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio lowered the firm’s price target on Sangamo Therapeutics to $5 from $15 and keeps a Buy rating on the shares post the Q1 results. While encouraged by the progress on the pipeline and "intrigued" by the company’s neurology compounds, the analyst dropped the price target to reflect opportunities in the late stage pipeline and the restructuring. The firm continues to find SSangamo shares attractive at current levels "ahead of the many near-term catalysts."